HGF and glioblastoma: In this standpoint, our purpose was to evaluate the prognostic and therapeutic significance of c-Met, HGF and VEGFR2 expression, together with microvessel density (MVD), in patients with recurrent GBM undergoing second-line chemotherapy with bevacizumab-based therapy.